PURPOSE: To compare dose volume histograms of intensity-modulated proton therapy (IMPT) with those of intensity-modulated radiation therapy (IMRT) and passive scattering proton therapy (PSPT) for the treatment of stage IIIB non-small-cell lung cancer (NSCLC) and to explore the possibility of individualized radical radiotherapy. METHODS AND MATERIALS: Dose volume histograms designed to deliver IMRT at 60 to 63 Gy, PSPT at 74 Gy, and IMPT at the same doses were compared and the use of individualized radical radiotherapy was assessed in patients with extensive stage IIIB NSCLC (n = 10 patients for each approach). These patients were selected based on their extensive disease and were considered to have no or borderline tolerance to IMRT at 60 to 63 Gy, based on the dose to normal tissue volume constraints (lung volume receiving 20 Gy [V20] of <35%, total mean lung dose <20 Gy; spinal cord dose, <45 Gy). The possibility of increasing the total tumor dose with IMPT for each patient without exceeding the dose volume constraints (maximum tolerated dose [MTD]) was also investigated. RESULTS: Compared with IMRT, IMPT spared more lung, heart, spinal cord, and esophagus, even with dose escalation from 63 Gy to 83.5 Gy, with a mean MTD of 74 Gy. Compared with PSPT, IMPT allowed further dose escalation from 74 Gy to a mean MTD of 84.4 Gy (range, 79.4-88.4 Gy) while all parameters of normal tissue sparing were kept at lower or similar levels. In addition, IMPT prevented lower-dose target coverage in patients with complicated tumor anatomies. CONCLUSIONS: IMPT reduces the dose to normal tissue and allows individualized radical radiotherapy for extensive stage IIIB NSCLC. Copyright 2010 Elsevier Inc. All rights reserved.
PURPOSE: To compare dose volume histograms of intensity-modulated proton therapy (IMPT) with those of intensity-modulated radiation therapy (IMRT) and passive scattering proton therapy (PSPT) for the treatment of stage IIIB non-small-cell lung cancer (NSCLC) and to explore the possibility of individualized radical radiotherapy. METHODS AND MATERIALS: Dose volume histograms designed to deliver IMRT at 60 to 63 Gy, PSPT at 74 Gy, and IMPT at the same doses were compared and the use of individualized radical radiotherapy was assessed in patients with extensive stage IIIB NSCLC (n = 10 patients for each approach). These patients were selected based on their extensive disease and were considered to have no or borderline tolerance to IMRT at 60 to 63 Gy, based on the dose to normal tissue volume constraints (lung volume receiving 20 Gy [V20] of <35%, total mean lung dose <20 Gy; spinal cord dose, <45 Gy). The possibility of increasing the total tumor dose with IMPT for each patient without exceeding the dose volume constraints (maximum tolerated dose [MTD]) was also investigated. RESULTS: Compared with IMRT, IMPT spared more lung, heart, spinal cord, and esophagus, even with dose escalation from 63 Gy to 83.5 Gy, with a mean MTD of 74 Gy. Compared with PSPT, IMPT allowed further dose escalation from 74 Gy to a mean MTD of 84.4 Gy (range, 79.4-88.4 Gy) while all parameters of normal tissue sparing were kept at lower or similar levels. In addition, IMPT prevented lower-dose target coverage in patients with complicated tumor anatomies. CONCLUSIONS: IMPT reduces the dose to normal tissue and allows individualized radical radiotherapy for extensive stage IIIB NSCLC. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Feng-Ming Kong; Randall K Ten Haken; Matthew J Schipper; Molly A Sullivan; Ming Chen; Carlos Lopez; Gregory P Kalemkerian; James A Hayman Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: Sue S Yom; Zhongxing Liao; H Helen Liu; Susan L Tucker; Chao-Su Hu; Xiong Wei; Xuanming Wang; Shulian Wang; Radhe Mohan; James D Cox; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2007-02-22 Impact factor: 7.038
Authors: Yixiu Kang; Xiaodong Zhang; Joe Y Chang; He Wang; Xiong Wei; Zhongxing Liao; Ritsuko Komaki; James D Cox; Peter A Balter; Helen Liu; X Ronald Zhu; Radhe Mohan; Lei Dong Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-01 Impact factor: 7.038
Authors: Hasan Murshed; H Helen Liu; Zhongxing Liao; Jerry L Barker; Xiaochun Wang; Susan L Tucker; Anurag Chandra; Thomas Guerrero; Craig Stevens; Joe Y Chang; Melinda Jeter; James D Cox; Ritsuko Komaki; Radhe Mohan; Joe Y Change Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-15 Impact factor: 7.038
Authors: H Helen Liu; Peter Balter; Teresa Tutt; Bum Choi; Joy Zhang; Catherine Wang; Melinda Chi; Dershan Luo; Tinsu Pan; Sandeep Hunjan; George Starkschall; Isaac Rosen; Karl Prado; Zhongxing Liao; Joe Chang; Ritsuko Komaki; James D Cox; Radhe Mohan; Lei Dong Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-29 Impact factor: 7.038
Authors: Joe Y Chang; Heng Li; X Ronald Zhu; Zhongxing Liao; Lina Zhao; Amy Liu; Yupeng Li; Narayan Sahoo; Falk Poenisch; Daniel R Gomez; Richard Wu; Michael Gillin; Xiaodong Zhang Journal: Int J Radiat Oncol Biol Phys Date: 2014-09-24 Impact factor: 7.038
Authors: Chenbin Liu; Steven E Schild; Joe Y Chang; Zhongxing Liao; Shawn Korte; Jiajian Shen; Xiaoning Ding; Yanle Hu; Yixiu Kang; Sameer R Keole; Terence T Sio; William W Wong; Narayan Sahoo; Martin Bues; Wei Liu Journal: Int J Radiat Oncol Biol Phys Date: 2018-02-14 Impact factor: 7.038